{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:44:04Z","timestamp":1765295044263,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.pvr.2019.100172","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T02:04:54Z","timestamp":1559959494000},"page":"100172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries"],"prefix":"10.1016","volume":"8","author":[{"given":"Asmaa","family":"Gohar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nourtan F.","family":"Abdeltawab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahla","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy A.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pvr.2019.100172_bib1","first-page":"33","article-title":"An introduction to global women health","volume":"1","author":"Nour","year":"2008","journal-title":"Rev. Obstet. Gynecol."},{"key":"10.1016\/j.pvr.2019.100172_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ebiom.2015.12.015","article-title":"Localization of viral antigens improves understanding of congenital rubella syndrome pathophysiology","volume":"3","author":"Garcia","year":"2015","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.pvr.2019.100172_bib3","first-page":"36","article-title":"Congenital rubella syndrome-major review","volume":"80","author":"Duszak","year":"2009","journal-title":"Optom. J. Am. Optom. Assoc."},{"issue":"9415","key":"10.1016\/j.pvr.2019.100172_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)15897-2","article-title":"Rubella","volume":"363","author":"Banatvala","year":"2004","journal-title":"Lancet"},{"issue":"suppl_1","key":"10.1016\/j.pvr.2019.100172_bib5","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/infdis\/jir123","article-title":"Progress toward measles and rubella elimination in Egypt","volume":"204","author":"El Sayed","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.pvr.2019.100172_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.21101\/cejph.a4010","article-title":"Seroprevalence of rubella antibodies among adult Egyptian females aged 20-30 years. Is there a need for rubella vaccination?","volume":"22","author":"Gadallah","year":"2014","journal-title":"Cent. Eur. J. Publ. Health"},{"issue":"S10","key":"10.1016\/j.pvr.2019.100172_bib7","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.23764","article-title":"HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women","volume":"113","author":"Gillison","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pvr.2019.100172_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"9","key":"10.1016\/j.pvr.2019.100172_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134618","article-title":"Developing the evidence base to inform best practice: a scoping study of breast and cervical cancer reviews in low-and middle-income countries","volume":"10","author":"Demment","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pvr.2019.100172_bib10","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.pvr.2019.100172_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ajog.2017.08.109","article-title":"Lessons learned from domestic and international human papillomavirus vaccination programs: a review","volume":"218","author":"Miller","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.pvr.2019.100172_bib12","first-page":"1839","article-title":"Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: a referral hospital-based study in Sicily","volume":"13","author":"Capra","year":"2017"},{"issue":"1","key":"10.1016\/j.pvr.2019.100172_bib13","first-page":"89","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012"},{"issue":"7308","key":"10.1016\/j.pvr.2019.100172_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(63)90434-3","article-title":"Rabbit cells susceptible to rubella virus","volume":"282","author":"Beale","year":"1963","journal-title":"The Lancet"},{"issue":"48","key":"10.1016\/j.pvr.2019.100172_bib15","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1016\/j.vaccine.2014.07.116","article-title":"Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins","volume":"32","author":"Bissett","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.pvr.2019.100172_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050296","article-title":"Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pvr.2019.100172_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4161\/hv.8485","article-title":"Cervarix\u00e2\u201e\u00a2, the GSK HPV-16\/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions","volume":"5","author":"Le Tallec","year":"2009","journal-title":"Hum. Vaccine"},{"issue":"2","key":"10.1016\/j.pvr.2019.100172_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jviromet.2010.04.006","article-title":"Development of a high-throughput rubella virus infectivity assay based on viral activation of caspases","volume":"167","author":"Bose","year":"2010","journal-title":"J. Virol Methods"},{"issue":"18","key":"10.1016\/j.pvr.2019.100172_bib19","article-title":"Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers","volume":"0934","author":"Shokri","year":"2018","journal-title":"J. Virol Methods"},{"issue":"5","key":"10.1016\/j.pvr.2019.100172_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4161\/hv.1.5.2126","article-title":"Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil\u0622\u00ae vaccine samples","volume":"1","author":"Shank-Retzlaff","year":"2005","journal-title":"Hum. Vaccine"},{"issue":"4","key":"10.1016\/j.pvr.2019.100172_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/hv.2.4.2989","article-title":"Evaluation of the thermal stability of Gardasil\u0622\u00ae","volume":"2","author":"Shank-Retzlaff","year":"2006","journal-title":"Hum. Vaccine"},{"issue":"7","key":"10.1016\/j.pvr.2019.100172_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4161\/hv.8485","article-title":"Cervarix- the GSK HPV-16\/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions","volume":"5","author":"Le Tallec","year":"2009","journal-title":"Hum. Vaccine"},{"issue":"1","key":"10.1016\/j.pvr.2019.100172_bib23","first-page":"68","article-title":"Microtitration of rubella virus in monovalent vaccinal products","volume":"40","author":"Esna-Ashari","year":"2011","journal-title":"Iran. J. Public Health"},{"issue":"9706","key":"10.1016\/j.pvr.2019.100172_bib24","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6\u0622\u00b7 4 years","volume":"374","author":"Group GVH-S","year":"2009","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.pvr.2019.100172_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"issue":"6","key":"10.1016\/j.pvr.2019.100172_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1086\/605410","article-title":"Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine","volume":"200","author":"LeBaron","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.pvr.2019.100172_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.184.2.473","article-title":"Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level","volume":"184","author":"Sornasse","year":"1996","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.pvr.2019.100172_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1128\/CVI.00090-07","article-title":"Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles","volume":"14","author":"Garcia-Pieres","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"issue":"4","key":"10.1016\/j.pvr.2019.100172_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09629350310001599639","article-title":"Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination","volume":"12","author":"Pukhalsky","year":"2003","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.pvr.2019.100172_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cyto.2009.12.002","article-title":"Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees","volume":"50","author":"Dhiman","year":"2010","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.pvr.2019.100172_bib31","first-page":"1738","article-title":"Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae","volume":"17","author":"Woo","year":"2007","journal-title":"J. Microbiol. Biotechnol."},{"issue":"4","key":"10.1016\/j.pvr.2019.100172_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/mpat.1996.0113","article-title":"Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles","volume":"22","author":"Dupuy","year":"1997","journal-title":"Microb. Pathog."},{"issue":"2","key":"10.1016\/j.pvr.2019.100172_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/376505","article-title":"Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles","volume":"188","author":"Pinto","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"23","key":"10.1016\/j.pvr.2019.100172_bib34","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2012.03.022","article-title":"Parental and societal values for the risks and benefits of childhood combination vaccines","volume":"30","author":"Gidengil","year":"2012","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.pvr.2019.100172_bib35","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.vaccine.2015.04.020","article-title":"Immune overload: parental attitudes toward combination and single antigen vaccines","volume":"33","author":"Hulsey","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.pvr.2019.100172_bib36","first-page":"359","article-title":"Immune responses after 2 versus 3 doses of HPV vaccination up to 4\u0622\u00bd years after vaccination: an observational study among Dutch routinely vaccinated girls","volume":"215","author":"Donken","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pvr.2019.100172_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fcimb.2019.00031","article-title":"The combination vaccine adjuvantsystem alum\/c-di-AMP results in quantitative and qualitative enhanced immune responses post immunization","volume":"9","author":"Ebensen","year":"2019","journal-title":"Front Cell Infect. Microbiol."},{"key":"10.1016\/j.pvr.2019.100172_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852119300047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852119300047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:03:47Z","timestamp":1762513427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852119300047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"alternative-id":["S2405852119300047"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2019.100172","relation":{},"ISSN":["2405-8521"],"issn-type":[{"type":"print","value":"2405-8521"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2019.100172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100172"}}